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Rectal and oral absorption of methylprednisolone acetate 
Rectal absorption of methylprednisolone acetate and oral absorption of methylprednisolone and 
methylprednisolone acetate were investigated in a single-dose 3-way crossover study of 12 
normal male volunteers. The median value of bioavailability (relative to oral dose) of 
methylprednisolone acetate based on unchanged methylprednisolone plasma levels was 14.2% 
after rectal administration. suggesting that the drug exerts its therapeutic effect topically rather 
than systemically. 1n contrast. the median of total radioactivity in urine (as a percentage of 
rectal dose) was 34.3% (range. 4.52% to 58.8%). suggesting partial bacterial metabolism in the 
rectum prior to absorption. Mean bioavailability (relative to oral administration of 
methylprednisolone acetate) of methylprednisolone after oral administration was 89.9%. 
indicating somewhat better systemic availability of the ester than the alcohol. The average 
apparent elimination rate constant for methylprednisolone after oral administration of both ester 
and alcohol was 0.290 hr-'. corresponding to a half-life of 2.39 hr. 
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Methylprednisolone acetate (Depo-Medrol) 
is a potent glucocorticoid used intramuscularly 
in aqueous suspension for patients with adrenal 
insufficiency or dermatoses." 3 A different 
aqueous suspension of this steroid has also been 
used as a retention enema (Medrol Enpak) for 
the treatment of patients with ulcerative colitis. 
Rectal absorption of corticosteroids has not 
been studied extensively and it is still not 
known whether corticosteroid enemas are lo-
cally effective8 , 11 or systemically effective. 5 In 
I study, the 24-hr urinary excretion of 14C_ 
labeled prednisone was found to be 72% of the 
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rectal dose. 4 Spencer et al. 13 studied the rectal 
absorption of radioactive 6-a-methylpredniso-
lone and reported 18% to 64% radioactive uri-
nary excretion of the rectal dose in 48 hr. In yet 
another study, rectal absorption of radioactive 
methylprednisolone was found to be about 22% 
that of oral absorption. to Data on rectal absorp-
tion of methylprednisolone acetate have not 
been reported to date. We report the results of a 
single-dose 3-treatment crossover study de-
signed to determine bioavailability of methyl-
prednisolone acetate after rectal administration. 
Materials and methods 
Protocol. Twelve normal, healthy male sub-
jects (aged, 22 to 44 yr; body weight, 60 to 82 
kg) were selected for the study. 
All study subjects received no steroid prep-
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Table I. Treatment schedules 
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Time period 
Phase I 
I 
Phase II 
I 
Phase III 
Group Subjects (week 1) (week 2) (week 3) 
I 2,4,9, II 
II 3, 5, 10, 12 
III 1,6,7,8 
aration for a period of 60 days preceding the 
study. They received no barbiturates or other 
enzyme inducers from 30 days before the study 
until its completion. They received no other 
medication or alcoholic beverages for a period 
beginning 7 days before the study until its 
completion. 
The treatments were as follows: treatment 
A-lO ml aqueous suspension of methylpred-
nisolone, 3.60 mg/ml (equivalent to 4.0 mg/ml 
of methylprednisolone acetate) administered 
orally; treatment B-lO ml aqueous suspension 
of methylprednisolone acetate, 4 mg/ml orally; 
treatment C-methylprednisolone acetate sus-
pension formulated to contain 50 JLCi 3H_ 
methylprednisolone acetate (6-a-methylpredni-
solone-2 I-acetate I,2,4-3H); a dose of 40 mg 
(specific activity, 1.25 JLCilmg) was added to 
30 ml warm water and administered as a reten-
tion enema. 
The subjects fasted overnight (from 10 P.M.) 
until 4 hr after administration of each treatment. 
The oral doses were taken in the morning (about 
8 A.M.) with 180 ml water. The treatment 
schedules are shown in Table I. 
Sampling. Blood samples were drawn at 0 hr 
and then again following treatments A, B, and 
C at \6, I, 2, 3, 4, 6, 8, 10, 12, and 14 hr. 
Samples following treatments Band C were 
also collected at 24 and 36 hr after dosing. A 
blood sample was drawn immediately after 
administration of the enema in treatment C. 
All blood specimens were drawn by 7-ml 
Vacutainers of 50 mg sodium fluoride and 5 mg 
thymol [sodium fluoride was found to inhibit 
hydrolysis of methylprednisolone acetate to 
methylprednisolone (alcohol) in fresh human 
blood2]. 
Urine and fecal collections were made during 
24 hr for 5 consecutive days following treatment 
A 
B 
C 
B C 
C A 
A B 
Table II. Results of HPLC assay of samples 
from different treatments 
Amount Equivalent of 
of steroid * methylprednisolone 
Treatment (mg) (mg) 
A 32.8 32.8 
B 36.6 32.9 
C 36.8 33.1 
"Average of 3 determinations. 
C only. Urine samples were collected in 
polyethylene containers. The total volume from 
each collection was measured and an aliquot kept 
at - 2fJ' for subsequent assay for total radioac-
tivity. Fecal samples were collected in I-gallon 
empty paint cans. Fecal samples were homoge-
nized with I to 2 times their weight of water and 
an aliquot was kept for subsequent assay. 
Determination of actual doses for different 
treatments. The contents of I vial from each 
treatment were dissolved in 500 ml methanol. 
Three aliquots of each were analyzed by high-
pressure liquid chromatography (HPLC) for 
methylprednisolone (treatment A) or methyl-
prednisolone acetate (treatments B and C). The 
averages of the assays are listed in Table II. For 
treatment C, the radioactivity of the same bottle 
was also determined by scintillation counting. 
The 36.8 mg methylprednisolone acetate or 
33.1 mg methylprednisolone shown in Table II 
were equivalent to 52 /LCi. After each treatment 
C, the residual radioactivity in the enema bag 
and tubing was measured and subtracted from 
52 JLCi to yield the radioactive dose for each 
subject. The radioactive dose was then con-
verted to milligrams of methylprednisolone by 
use of HPLC assay results shown in Table II. 
Assay of plasma, urine, and fecal samples. 
Two milliliters of plasma were used for deter-
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Fig. 1. Plot of average plasma concentrations of methylprednisolone against time. Treatment A, e; 
treatment B, 0; treatment C, •. 
Table Ill. Time of first bowel movement, radioactivity in feces and urine, and the total 
area under the curve for methylprednisolone following rectal administration of 
methylprednisolone acetate (treatment C) 
Time of first 
Radioactivity 
(% of dose) 
bowel movement 
I 
(AUe 0 - ooJc 
Subject (hr) Urine Feces [eng Iml) x hr] 
I 10.7 50.3 22.6 413 
2 23.0 58.8 13.5 166 
3 8.25 39.0 22.1 234 
4 22.0 49.6 10.6 171 
5 1.17 4.52 69.3 -* 
6 36.0 45.2 14.6 315 
7 6.17 45.9 19.6 211 
8 1.17 5.13 65.6 -* 
9 1.67 7.31 66.7 -* 
10 1.33 4.68 69.9 -* 
II 7.5 29.6 33.4 283 
12 2.25 13.1 63.5 115 
Median 34.3 28.0 169 
*Concentrations in all samples were too low for detection by HPLC assay. 
mination of methylprednisolone and methyl-
prednisolone acetate by means of an HPLC 
method. 2 The chromatographic separations were 
done on a /-L- Bondapak CI8 column and the car-
rier solvent was methanol, water, and acetic 
acid in a ratio of 56: 39: 5 by volume at a flow 
rate of 1.6 ml/min. The quality-control samples 
were prepared by using plasma obtained from 
other volunteers. The blood was collected in 
Vacutainers containing sodium fluoride, and the 
plasma was spiked with methylprednisolone 
and methylprednisolone acetate to produce con-
centrations of 140 and 100 ng/ml, respectively. 
An assay on at least 1 quality-control sample 
was run each day that unknowns were assayed. 
Urine (l or 1.5 ml) from each sample col-
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Table IV. Bioavailability (relative to oral dose) of methylprednisolone acetate after 
rectal administration 
bioavailability of 
(AUe 0 - x)B Dose B (AUe O-xJc Dose e e (~) =(AUeO-xJclDc x 100 
o (AUeO-X)slDs Subject [(nglm/) xhr] (mg) [eng 1m/) x hr] (mg) 
I 862 32.9 413 28.7 54.9 
2 1,373 32.9 166 27.8 14.3 
3 727 32.9 234 29.8 35.5 
4 1,241 32.9 171 29.4 15.4 
5 792 32.9 -* 29.2 -t 
6 1,554 32.9 315 29.9 22.3 
7 1,654 32.9 211 29.6 14.2 
8 1,096 32.9 -* 26.9 -t 
9 1,253 32.9 -* 30.5 -t 
10 1,175 32.9 * 27.5 -t 
II 1,830 32.9 283 27.7 25.3 
12 990 32.9 115 27.2 14.1 
Median 14.2 
-The area in these subjects was considered to be 0 because in all samples the methylprednisolone plasma levels were too low for detection 
by assay. 
tFor calculation of the median, these bioavailabilities were considered to be equal to O. 
lected following treatment C was counted in a 
liquid scintillation counter (Packard 3320) for 
total radioactivity. The counts per minute were 
converted to disintegrations per minute by use 
of a quench factor. 
Fecal homogenates (0.1 to 1 gm) were 
weighed directly into combustion cones and 
dried overnight at room temperature. The sam-
ples were combusted using the Packard Tri Carb 
Sample Oxidizer Model 306. The instrument 
collected the water in a scintillation vial and 
added scintillation fluid automatically. A piece 
of filter paper was burned after each sample and 
the water was collected in the vial, used for 
collecting water from the sample. The recovery 
of radioactivity by the combustion procedure 
was determined by adding a known amount of 
radioactivity to the fecal samples, combusting 
the samples, and counting the collected water. 
The average recovery from 4 determinations 
was 98.3% (coefficient of variation, 7.17%). 
Results 
Precision of analytical method. The preci-
sion of the HPLC method was indicated by co-
efficients of variation calculated from 2 types of 
data-those calculated from concentrations es-
timated by standard curve data were 4.2% for 
methylprednisolone and 4.6% for methylpred-
nisolone acetate and those of concentrations es-
timated by analysis of the quality-control sam-
ples were 6.5% for methylprednisolone and 
7.0% for methylprednisolone acetate (quality-
control samples analyzed over 16 days). 
HPLC analysis of plasma samples. All 
plasma samples collected after oral (treatment 
B) and rectal (treatment C) methylprednisolone 
acetate contained only methylprednisolone al-
cohol and no intact ester. Average plasma con-
centrations of methylprednisolone after treat-
ments A, B, and C are plotted in Fig. 1. The 
concentrations of methylprednisolone at 24 and 
36 hr after treatments Band C were too low for 
detection by the HPLC assay method (i .e., ::S 5 
ng/mi). The plasma concentrations of methyl-
prednisolone in all samples collected from sub-
jects who had their first bowel movements 
within 2 hr of rectal administration of methyl-
prednisolone acetate were also too low for de-
tection by HPLC assay. 
Total area (AUC 0- 00 ) under the methylpred-
nisolone plasma concentration- time curve was 
calculated for each subject after each treatment, 
where feasible, by use of equations I to 3: 
Aue O-x = AUe O-T + CT /{3 (I) 
In e = In B - (3t (2) 
CT =e<lnB-/3T) (3) 
In equations I to 3, AUC O-T is the area esti-
mated by trapezoidal rule up to time T; T is the 
last sampling time when the observed concen-
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Table V. Bioavailability (relative to oral administration of methylprednisolone acetate) 
of methylprednisolone after oral administration 
hio(lvailahiliry of 
(AVe 0 - :x)A (AVe O-X)/I A *(%) = (AVe 0 - X)A/D A x 100 
Subject [(ng Iml) x hr] [(ng 1m/) x hr] (AVe 0 - X)B/DB 
I 709 862 82.5 
2 1,196 1,373 87.3 
3 746 727 103 
4 1,134 1,241 91.7 
5 836 792 106 
6 1,129 1,554 72.9 
7 1,392 1,654 84.4 
8 828 1,096 75.8 
9 962 1,253 77.0 
10 1,216 1,175 104 
II 1,250 1,330 94.3 
12 1,250 990 100 
Median 1,060 1,208 89.5 
Mean 1,032 1,171 89.9t 
c.v.t(%) 21.3 24.9 13.0 
*DA is dose in treatment A-32.S mg methylprednisolone. D8 is dose in treatment B-36.6 mg methylprednisolone acetate, equivalent to 
32.9 mg methylprednisolone. 
tMean ratio differs from 100% (t = 300; 0.02 > P > 0.01.). 
*Coefficients of variation. 
tration was higher than the sensitivity limit of 
the HPLC assay; C is the methylprednisolone 
plasma concentration in the terminal log-linear 
phase; f3 is the apparent elimination rate con-
stant obtained by the method of least squares 
and equation 2; and CT is the estimated plasma 
concentration at time T obtained by use of 
equation 3. The areas after treatment Care 
listed in Table III, while those after treatments 
A and B are listed in Table V. 
Bioavailability of methylprednisolone acetate 
after rectal administration, relative to oral ad-
ministration of methylprednisolone acetate, was 
calculated as the dose-corrected ratio of the ap-
propriate areas for each subject and these are 
listed in the last column of Table I V. The me-
dian value of 14.2% indicated low systemic 
availability. The dose of treatment B (DB) was 
the actual dose found by HPLC assay (Table II), 
while the dose of treatment C (Dc) was calcu-
lated from the difference of the Table II value 
and the measured radioactivity remaining in the 
enema bag and tubing after drug administration 
to each subject (Table I V). 
Bioavailability of oral methylprednisolone 
(alcohol) relative to oral methylprednisolone 
acetate was estimated from the dose-corrected 
areas under the plasma methylprednisolone-
time curves; the areas and the individual subject 
bioavailabilities are listed in Table V. It is evi-
dent that the bioavailability of methylpredniso-
lone after the acetate was slightly greater than 
that after the alcohol. 
Radioactivity measurements. Recoveries of 
radioactivity (as a percentage of dose) excreted 
in 5 days in urine and feces are listed in Table 
III. Total recovery of radioactivity (sum of 
urine and feces) averaged 68.7% (coefficient of 
variation, 9.2%). Most of the radioactivity in 
both urine and feces was excreted in the first 24 
hr. The average of the first-day excretion in 
urine was 81% of that excreted in 5 days, and 
the average of the first-day excretion in feces 
was 87% of that excreted in 5 days. There was 
a curvilinear relationship between the recovery 
of radioactivity in urine in 5 days and the time 
of the first bowel movement; the shorter the 
time to the first bowel movement, the lower 
the excretion of radioactivity in urine (see 
Table III). 
Discussion 
The absence of methylprednisolone acetate in 
plasma most probably resulted from rapid hy-
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Table VI. Average kinetic parameters for methylprednisolone 
Parameter 
Apparent elimination rate 
constant (he') 
Apparent elimination t'/2 
(hr) 
Apparent plasma clearance 
IIhr 
lI(kg x hr) 
Vdarea 
Value calculated following 
Treatment A 
0.290 (9.72)* 
2.39 
33.2 (22.5) 
0.492 (24.5) 
Treatment B 
0.291 (12.8)* 
2.38 
29.9 (27.0) 
0.444 (29.2) 
I 
IIkg 
115 (22.9) 103 (26.5) 
'The numbers in parentheses are coefficients of variation (%). 
drolysis of the ester during absorption or in the 
liver before it reached the general circulation. 
Preliminary work2 indicated that collection of 
blood in containers of sodium fluoride inhibited 
hydrolysis of the ester between the time blood 
was drawn and the time of assay. 
Low-level rectal absorption of methylpred-
nisolone acetate relative to oral absorption is 
indicated by the mean plasma concentrations of 
methylprednisolone shown in Fig. I and by the 
median relative bioavailability value of 14.2% 
in Table IV. It should be noted that these results 
were obtained with the HPLC assay procedure, 
which specifically measured methylpredniso-
lone and was capable of also measuring 
methylprednisolone acetate if the latter had ap-
peared in plasma. This low relative bioavail-
ability stands in contrast with the median value 
of 34.3% for recovery of radioactivity in the 
urine (Table III). A feasible explanation is bac-
terial metabolism of the drug in the colon fol-
lowed by rectal absorption of a metabolite or 
metabolites along with the original acetate or 
methylprednisolone, its hydrolysis product. 
That bacteria and molds can oxidize and re-
duce steroids has been known for many years. 
Peterson et al. 9 reported that when hydrocor-
tisone was incubated with feces, the steroid was 
completely metabolized in 4 hr. Nabarro et al. 7 
observed an increase in the urinary excretion of 
17-ketosteroids after rectal infusion of hydro-
cortisone. Urinary excretion of 17-ketosteroids 
returned to normal when bacterial activity in the 
lower gastrointestinal tract was reduced with 
neomycin before or during the hydrocortisone 
1.69 (22.6) 1.53 (29.3) 
infusion. Similar observations were made by 
Wade et al. 14 To test this explanation, total ra-
dioactivity was measured in plasma samples of 
Subjects 1 and 2. The methylprednisolone 
plasma concentrations estimated from total ra-
dioactivity measurements were considerably 
higher than those obtained by the HPLC meth-
od, indicating that total radioactivity in plasma, 
and most probably in urine, represented both 
methylprednisolone and metabolites. Unfortu-
nately, unchanged methylprednisolone could 
not be measured in urine because of interferring 
peaks. We therefore believe that rectal absorp-
tion of methylprednisolone acetate is low, indi-
cating a topical rather than systemic effect 
(median, 14.2%; range, 0% to 54.9%; Table 
IV), rather than high reflected by values for 
recovery of radioactivity in urine (Table III). 
Our results indicate one pitfall in use of total 
recovery of radioactivity in urine4 • 10, 13 to 
reflect rectal absorption of any drug metabo-
lized by bacteria in the lower gastrointestinal 
tract. 
In our study, suspensions of methylpred-
nisolone (alcohol) were less well absorbed than 
suspensions of methylprednisolone acetate when 
taken orally, as indicated by the mean relative 
bioavailability value of 89.9%, which, by the t 
test, differed from the 100% (p < 0.02) obtain-
able if the mean bioavailabilities had been equal 
(Table V). 
Methylprednisolone kinetics. The apparent 
elimination rate constants from fall off of meth-
ylprednisolone plasma concentration curves 
with time after treatments A and B were calcu-
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Fig. 2. Plot of average plasma concentrations of methylprednisolone against time. Treatment A. e; 
treatment B, o. The lines drawn through the points are based on a computer fitting of the plasma 
concentrations to the polyexponential equations given below: 
Treatment A: Cp = 86.5e- 2.37t + 630e-O.2991 - 7l7e-o.64tl 
Treatment B: Cp = 487 e- 1.1 tl + 685eo.291l - 117 e- O.7:l~1 
lated for each subject by use of equation 2 and 
the method of least squares. 
The apparent plasma clearance, elp/FF, * 
was calculated by applying equation 4: 
Cl /FF* = Dose 
p AUC 0-00 (4) 
In equation 4, F is the absorbed fraction of the 
dose (0 :::::; F:::::; I) and F* is the "first-pass" 
bioavailability factor (0 :::::; F* :::::; I). The AUe 
0-00 is the total area under the methylpred-
nisolone plasma concentration-time curves cal-
culated by equation I. 
V darea values (actually V darea/FF*) were es-
timated by means of equation 5: 
(5) 
Table VI summarizes the kinetic parameters 
obtained from this study. Virtually identical ki-
netic parameters were obtained when the steroid 
ester and the alcohol were administered orally. 
Fitting of oral data to polyexponential 
equation. The average plasma concentration-
time data obtained after oral administration of 
methylprednisolone and its acetate (treatments 
A and B) were stripped using the program 
eSTRIP. 12 The data were then fitted to the ap-
propriate polyexponential equations using the 
program NONLINs and to the preliminary esti-
mates of the parameters obtained by use of the 
program eSTRIP. In Fig. 2, the solid circles 
and open circles are the mean plasma concen-
trations of methylprednisolone after treatments 
A and B, whereas the lines drawn through the 
points are based on the NONLIN computer 
fitting of the plasma concentrations to polyex-
ponential equations. The areas under the plasma 
concentration- time curves obtained by integra-
tion of the polyexponential equations15 were 
1,025 and 1,172 [(ng/ml) x hr] for treatments 
A and B, while areas of 1,026 and 1,173 
[(ng/m!) x hr] were calculated by the trape-
zoidal rule. 
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